Tidal Investments’s Neurocrine Biosciences NBIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.69M Buy
28,415
+17,070
+150% +$2.26M 0.01% 926
2025
Q4
$1.61M Buy
11,345
+3,612
+47% +$523K ﹤0.01% 1040
2025
Q3
$1.09M Sell
7,733
-594
-7% -$80.5K ﹤0.01% 1179
2025
Q2
$1.05M Sell
8,327
-3,760
-31% -$431K 0.01% 1017
2025
Q1
$1.34M Buy
12,087
+2,662
+28% +$337K 0.01% 856
2024
Q4
$1.29M Sell
9,425
-5,618
-37% -$695K 0.01% 886
2024
Q3
$1.73M Buy
15,043
+5,197
+53% +$712K 0.02% 733
2024
Q2
$1.36M Buy
9,846
+304
+3% +$41.7K 0.02% 742
2024
Q1
$1.32M Buy
9,542
+3,497
+58% +$478K 0.02% 756
2023
Q4
$796K Buy
6,045
+3,940
+187% +$454K 0.02% 737
2023
Q3
$237K Buy
+2,105
New +$222K 0.01% 1148
2023
Q2
Sell
-2,057
Closed -$208K 1361
2023
Q1
$208K Buy
+2,057
New +$214K 0.01% 1178
2022
Q2
Sell
-3,144
Closed -$295K 1157
2022
Q1
$295K Buy
3,144
+402
+15% +$34.1K 0.01% 824
2021
Q4
$234K Buy
2,742
+490
+22% +$45.1K 0.01% 849
2021
Q3
$216K Buy
+2,252
New +$213K 0.01% 769
2021
Q2
Sell
-2,579
Closed -$251K 739
2021
Q1
$251K Buy
+2,579
New +$270K 0.01% 478
2020
Q3
Sell
-2,246
Closed -$274K 295
2020
Q2
$274K Buy
+2,246
New +$248K 0.04% 239

Other funds holding NBIX

Tidal Investments's NBIX Position: Q1 2026 in Review

Tidal Investments increased its Neurocrine Biosciences (NBIX) stake by 150% in Q1 2026, buying an estimated $2.26M and bringing the position to 28,415 shares worth $3.69M. The position accounts for 0.01% of the portfolio, ranked #926.

Tidal Investments first reported a position in NBIX in Q2 2020 and has held it in 17 quarters since. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Tidal Investments held 28,415 shares of Neurocrine Biosciences worth $3.69M as of Q1 2026.
  • Tidal Investments bought 17,070 Neurocrine Biosciences shares in Q1 2026, an estimated $2.26M.
  • Neurocrine Biosciences made up 0.01% of Tidal Investments's portfolio in Q1 2026, its #926 holding.
  • Tidal Investments first reported a position in Neurocrine Biosciences in Q2 2020 and has held it in 17 quarters since.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Tidal Investments's 13F filing for Q1 2026, filed 15 May 2026.